BioCryst (BCRX) Pharmaceuticals announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst price target raised to $15 from $13 at BofA
- BioCryst’s Strategic Sale and Debt Retirement Strengthen Financial Position and Justify Buy Rating
- BioCryst Sells BioCryst Ireland to Neopharmed Gentili
- BioCryst price target raised to $18 from $16 at Wedbush
- BioCryst Sells European ORLADEYO Business for $264M